Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules. “Combining Chemaxon’s expertise with Certara’s biosimulation capabilities provides life sciences companies with unique solutions to enhance productivity and increase their scientific innovation success rates,” said William Feehery, Certara’s CEO.
Read the full article: Certara Completes Acquisition of Chemaxon //
Source: https://www.globenewswire.com/news-release/2024/10/02/2957362/0/en/Certara-Completes-Acquisition-of-Chemaxon.html